{
  "date": "2026-02-26",
  "items": [
    {
      "source": "pubmed",
      "pmid": "41628407",
      "doi": "10.1212/WNL.0000000000214484",
      "title": "Evaluating Prehospital Stroke Scales for Large Vessel Occlusion: A Systematic Review and Network Meta-Analysis.",
      "abstract": "Ischemic stroke remains a leading cause of death and disability worldwide, with large vessel occlusion (LVO) accounting for a disproportionate share of poststroke morbidity. Early identification of LVO is essential for timely intervention with endovascular thrombectomy; however, the clinical scales currently used for triage vary widely in their application and accuracy. This study assesses the diagnostic performance of clinical stroke scales in predicting LVO. A systematic review was conducted to identify studies evaluating the diagnostic accuracy of prehospital stroke scales for detecting LVO. Pooled sensitivity and specificity were estimated using a bivariate random-effects model, with diagnostic performance further assessed through summary receiver operating characteristic (ROC) curves and area under the curve (AUC) analysis. A Bayesian network meta-analysis was conducted to rank the scales using surface under the cumulative ranking (SUCRA) probabilities, and post hoc analyses were performed to evaluate publication bias. A total of 58 studies comprising 58,381 patients and 33 unique stroke scales were included in the final analysis. The studies, published between 2014 and 2023, were primarily conducted in North America (50%) and Europe (26%), with a median sample size of 473 participants. Pooled sensitivity ranged from 0.30 (HEMIPARESIS) to 0.99 (LARIO) while specificity varied from 0.34 (FANG) to 0.94 (HEMIPLEGIA). Among the highest-performing scales overall were LARIO (AUC = 0.983), FPSS (AUC = 0.896), FACE2AD (AUC = 0.876), and ACT-FAST (AUC = 0.873). In prehospital settings, FPSS (AUC = 0.896), FAST VAN (AUC = 0.878), and FACE2AD (AUC = 0.876) demonstrated strong performance while LARIO (AUC = 0.983) and ACT-FAST (AUC = 0.883) showed the highest accuracy in hospital settings. Bayesian network meta-analysis identified POMONA (SUCRA = 0.877), NIHSS (0.856), sNIHSS EMS (0.854), G-FAST (0.823), and SAFE (0.788) as the top-ranked scales. Funnel plot analysis revealed minimal publication bias among the most frequently evaluated tools, including RACE, CPSS, and NIHSS. Numerous clinical scales are available for detecting LVO in the prehospital setting. While several demonstrate strong performance in specific contexts, there remains a clear need for a simple, accurate, and generalizable tool to reliably identify patients with LVO across diverse clinical environments.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Feb-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41628407/",
      "summary_ja": "背景：虚血性脳卒中は世界的に主要な死因・障害原因であり、大血管閉塞（LVO）が重篤な後遺症の大部分を占める。早期のLVO同定は血管内血栓除去術の迅速な介入に不可欠だが、現行の前病院段階で用いられる脳卒中スケールは適用法や精度にばらつきがある。  \n方法：LVO検出の診断精度を評価した研究を系統的にレビューし、58件・58,381例・33種類のスケールを対象に二変量ランダム効果モデルで感度・特異度を統合。ROC曲線下面積（AUC）解析やベイズネットワークメタ解析でスケールの順位付け（SUCRA値）を行い、出版バイアスも検討した。  \n結果：感度は0.30（HEMIPARESIS）から0.99（LARIO）、特異度は0.34（FANG）から0.94（HEMIPLEGIA）まで幅があった。総合的にLARIO（AUC=0.983）、FPSS（0.896）、FACE2AD（0.876）、ACT-FAST（0.873）が高性能。前病院ではFPSS、FAST VAN、FACE2ADが優れ、病院内ではLARIOとACT-FASTが最も高精度。ベイズ解析ではPOMONA、NIHSS、sNIHSS EMS、G-FAST、SAFEが上位に。出版バイアスは主要スケールでほぼ認められなかった。  \n結論：多様な前病院用スケールが存在し一部は高精度だが、簡便かつ汎用的にLVOを確実に識別できるツールの開発が依然として求められている。",
      "summary_short_ja": "本研究は、脳梗塞の大血管閉塞（LVO）を早期に識別するための救急前診断スケールの診断精度を系統的に評価した。58件の研究（58,381例）を対象にメタ解析を行い、LARIOやFPSS、FACE2AD、ACT-FASTなどが高い感度・特異度を示した。ベイズネットワーク解析ではPOMONAやNIHSSが上位にランク付けされたが、現場で広く使える簡便かつ汎用性の高いスケールの開発が依然として求められている。",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41610380",
      "doi": "10.1001/jamaneurol.2023.5319",
      "title": "Postmortem Associations Between Alzheimer Disease Pathology and Plasma pTau217, GFAP, and NfL in AD and AD-Related Dementias.",
      "abstract": "Alzheimer disease (AD) and its related disorders (ADRDs) are characterized by a high frequency of copathologies. We aimed to determine the specificity of plasma pTau217, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) for AD neuropathological change (ADNC) in the presence of common ADRD copathologies. pTau217, GFAP, and NfL were measured using S-PLEX immunoassays from Meso Scale Discovery in banked plasma samples from 2 groups of participants in the Massachusetts Alzheimer's Disease Research Center (MADRC) Longitudinal Cohort study: (1) participants spanning the cognitive spectrum, who underwent brain autopsy, and blood collection within 6 years before death, and (2) participants with normal cognition and no neurologic diagnosis during 5 years of follow-up, but no autopsy data (normal controls [NCs]). Cross-sectional associations between biomarker levels and ADNC, primary neuropathologic diagnosis (NPDx1), and presence of non-AD copathologies were evaluated using linear regression models controlling for age, sex, and time to death. One hundred eighty-seven participants with brain autopsy (NPDx1: AD n = 85; other n = 102; mean age: 74.3 years, 38.5% female; interval blood collection-death [mean ± SD]: 2.8 ± 1.6 years) and 67 NC without brain autopsy (mean age: 66.5 years, 71.6% female) were included. pTau217, but not GFAP, levels increased stepwise with increasing Thal phases (β = 0.61; 95% CI [0.24-0.97] to β = 0.91 [0.55-1.27]) and Braak stages (β = 0.59; [0.16-1.01] to β = 0.74 [0.33-1.15]). Although 23% of individuals with a non-AD NPDx1 had increased pTau217 levels using a cutoff defined by the contrast between ADNC and NC, the majority (62%) had intermediate/high ADNC copathology and the remaining pTau217+ individuals had borderline increased levels. By contrast, 48% of individuals without ADNC had increased GFAP levels. pTau217 and GFAP were not different in the presence or absence of cerebral amyloid angiopathy, α-synuclein or TDP-43 proteinopathies, or primary tauopathies. NfL was not specifically associated with ADNC. Plasma pTau217, but not GFAP or NfL, levels accurately reflect the presence of ADNC in the brain even in individuals with an NPDx1 of a non-AD dementia. Thus, a positive plasma pTau217 test in an individual with a suspected non-AD dementia should not necessarily be considered a misdiagnosis of the presumed non-AD dementia or as a false positive, but rather as evidence of ADNC copathology.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Feb-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41610380/",
      "summary_ja": "背景：アルツハイマー病（AD）および関連認知症（ADRD）は複数の病理が共存することが多い。本研究は、血漿中のpTau217、GFAP、NfLがAD神経病理変化（ADNC）に特異的かを、共存するADRD病理の影響下で検証した。  \n方法：マサチューセッツAD研究センターの縦断コホートから、死後解剖を受けた認知機能の異なる187名と、正常認知の67名（解剖なし）を対象に、血漿中バイオマーカーをS-PLEX免疫測定法で測定。ADNCや他の病理との関連を線形回帰モデルで解析した。  \n結果：pTau217はThalフェーズやBraakステージの進行に伴い段階的に増加し、ADNCの存在を反映した。一方、GFAPはADNC非存在者の48%で増加し、NfLはADNCと特異的関連を示さなかった。非AD認知症群でもpTau217陽性者の多くは中間～高度のADNCを有していた。  \n結論：血漿pTau217はADNCの正確な指標であり、非AD認知症での陽性は誤診や偽陽性ではなく、ADNCの共存を示す重要な証拠である。GFAPやNfLはADNC特異性に乏しい。",
      "summary_short_ja": "本研究は、アルツハイマー病（AD）および関連認知症における脳病理変化（ADNC）と血漿中バイオマーカーpTau217、GFAP、NfLの関連を検討した。pTau217はADNCの進行度と相関し、非AD認知症患者でもADNCの共病理を反映した。一方、GFAPやNfLはADNC特異的でなかった。したがって、非AD認知症でのpTau217陽性は誤診ではなくADNCの共存を示す重要な指標と示唆される。",
      "disease": "dementia",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41610378",
      "doi": "10.1212/WNL.0000000000214612",
      "title": "Pediatric Hemorrhagic Moyamoya Disease: Clinical Course, Treatment, and Outcomes.",
      "abstract": "Pediatric hemorrhagic moyamoya disease (MMD) is a critical subtype associated with high morbidity; however, hemorrhage-specific prognostic factors remain poorly defined. The aim of this study was to define the clinical course, identify factors associated with hemorrhagic presentation and recurrence, and evaluate long-term outcomes in a large pediatric cohort. This retrospective cohort study included children diagnosed with MMD between 2003 and 2023. Hemorrhagic MMD was defined as acute intracranial hemorrhage on CT/MRI within 72 hours of symptom onset, excluding traumatic or aneurysmal causes. Standardized data collection encompassed Suzuki staging, posterior communicating artery (PcomA) and anterior choroidal artery (AChA) dilatation, modified Rankin Scale (mRS) scores at admission and follow-up, and recurrence events. Multivariable logistic regression and Cox proportional hazards models were used to identify factors associated with hemorrhagic MMD and stroke recurrence. Among 1,446 pediatric patients with MMD, 117 had hemorrhagic presentation. The hemorrhagic cohort was significantly older (mean age 10.9 ± 4.1 years vs 7.6 ± 4.5 years,  Hemorrhagic MMD is an aggressive subtype characterized by posterior collateral vulnerability, female predominance, and older age. Admission mRS score ≥2 and AChA dilatation are key factors strongly associated with adverse outcomes. Conventional angiographic classification does not demonstrate a significant association with hemorrhage outcome; assessment of the posterior circulation is critical for stratifying patient outcomes and guiding early intervention.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Feb-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41610378/",
      "summary_ja": "背景：小児の出血性もやもや病（MMD）は重篤な亜型であり、出血に特有の予後因子は十分に解明されていない。  \n方法：2003年から2023年に診断された小児MMD患者1,446例を対象に後ろ向きコホート研究を実施。出血性MMDは発症72時間以内の非外傷性・非動脈瘤性の急性頭蓋内出血と定義し、Suzuki分類、後交通動脈（PcomA）および前脈絡叢動脈（AChA）の拡張、修正Rankinスケール（mRS）スコア、再発イベントを収集。多変量ロジスティック回帰とCox比例ハザードモデルで出血性発症および再発の関連因子を解析。  \n結果：117例が出血性発症で、非出血例より年長（平均10.9歳対7.6歳）かつ女性に多い。入院時mRS≥2およびAChA拡張が悪性予後と強く関連。従来の血管造影分類は出血予後と有意な関連を示さなかった。  \n結論：出血性MMDは後方循環の脆弱性を特徴とし、早期介入の指標として後方循環評価が重要である。",
      "summary_short_ja": "小児出血性もやもや病（MMD）は高い罹患率を持つ重篤な亜型であり、本研究は2003～2023年の1,446例の小児MMD患者を対象に臨床経過、出血発症・再発因子、長期予後を検討した。出血例は平均年齢が高く女性に多く、後方循環の動脈拡張（特に前脈絡叢動脈拡張）と入院時のmRSスコア≥2が予後不良の主要因子であった。従来の血管造影分類は予後予測に有用でなく、後方循環評価が早期介入の指標となる。",
      "disease": "stroke",
      "section": "treatment"
    },
    {
      "source": "pubmed",
      "pmid": "41604611",
      "doi": "10.1002/alz.13859",
      "title": "Association Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages.",
      "abstract": "Changes in CSF and tau PET biomarkers of Alzheimer disease (AD) emerge years before clinical symptoms are observed. However, few studies have examined the temporal relationship between these measures. This study investigated whether longitudinal changes in CSF AD biomarkers were associated with  This study involved a retrospective analysis of cognitively unimpaired participants from the longitudinal observational Biomarkers of Cognitive Decline Among Normal Individuals cohort (NIH and Johns Hopkins University). Phosphorylated tau (p-tau) 181, total tau (t-tau), and β-amyloid (Aβ) A total of 120 cognitively unimpaired individuals (baseline age range 32-78 years; mean age 57 years; 60% female) were included in the analysis, including 78 participants with longitudinal CSF data (424 observations) and 42 additional participants contributing to cross-sectional analyses of initial CSF levels only. Results showed that higher levels of CSF p-tau These findings show that tau PET burden in Braak stage I and II subregions is associated with increases in CSF tau and p-tau over time, offering important insights into the relationships among key biomarkers for the diagnosis and staging of AD, although tau PET was collected at only a single time point, limiting inferences about the temporal evolution of PET-CSF relationships.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Feb-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41604611/",
      "summary_ja": "背景：アルツハイマー病（AD）の脳脊髄液（CSF）およびタウPETバイオマーカーの変化は、臨床症状出現の数年前から現れるが、これらの指標間の時間的関係は十分に解明されていない。  \n方法：認知機能に問題のない120名（平均年齢57歳、60％女性）を対象に、NIHとジョンズホプキンス大学の縦断的観察研究データを用いて、CSF中のリン酸化タウ（p-tau181）、全タウ（t-tau）、βアミロイド（Aβ）の変化と、初期のBraakステージにおけるタウPET負荷との関連を解析した。うち78名は縦断的CSFデータを持ち、42名は横断的データのみを提供。  \n結果：CSF中のp-tauおよびt-tauの増加率が高いほど、BraakステージIおよびIIのタウPET負荷が高いことが示された。  \n結論：初期BraakステージのタウPET負荷は、時間経過に伴うCSFタウおよびp-tauの増加と関連しており、ADの診断・病期評価における主要バイオマーカー間の関係理解に重要な知見を提供する。ただし、タウPETは単一時点での測定であり、PETとCSFの時間的変化の因果関係には限界がある。",
      "summary_short_ja": "本研究は認知機能に問題のない被験者120名を対象に、アルツハイマー病の脳脊髄液（CSF）バイオマーカーの長期変化と初期ブラーカーステージにおけるタウPET負荷の関連を検討した。結果、CSF中のリン酸化タウ（p-tau）および総タウ（t-tau）の増加が、ブラーカーステージI・IIのタウPET負荷の増大と関連していることが示された。これにより、AD診断・病期評価におけるバイオマーカー間の関係理解が進んだが、PETは単一時点の測定であり時間的変化の解明には限界がある。",
      "disease": "dementia",
      "section": "imaging"
    },
    {
      "source": "pubmed",
      "pmid": "41604609",
      "doi": "10.1007/s00259-023-06154-y",
      "title": "Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.",
      "abstract": "The α-synuclein (α-syn) seed amplification assay (SAA) has shown promising results for diagnosing dementia with Lewy bodies (DLB) using CSF samples. A barrier to implementing α-syn SAA clinically is the use of different protocols for the assay. It is unknown how different protocols perform in comparison with each other. We compared the performance of α-syn SAA across 4 laboratories using CSF samples of patients with DLB. This was a retrospective cross-sectional study that included data from 4 different European laboratories. We included probable patients with DLB with a positive dopamine transporter (DaT)-SCAN and known amyloid-β status who had mild-to-moderate dementia, along with age-matched and sex-matched controls. The α-syn SAA was run across 4 laboratories using different protocols varying α-syn concentration and plate reader settings. CSF samples were provided by a fifth independent laboratory, which also performed statistical and result analyses. We included 20 patients with DLB (mean age 67 ± 6 years, 60% male) and 10 controls (mean age 67 ± 2 years, 70% male). Neuropathologic confirmation was available for 2 patients with DLB. On average, the 4 laboratories achieved 78.8% sensitivity (minimum 55%, maximum 100%), 77.5% specificity (minimum 60%, maximum 100%), and 78.5% accuracy (minimum 57%, maximum 100%) for discriminating DLB from controls, but our findings show that diagnostic performance of SAA varied across laboratories: Lab A achieved 100% sensitivity (CI 84%-100%) and 100% specificity (CI 72%-100%); Lab B achieved 85% sensitivity (CI 64%-95%) and 90% specificity (CI 59%-99%); Lab C achieved 55% sensitivity (CI 34%-74%) and 60% specificity (CI 31%-83%); and Lab D achieved 75% sensitivity (CI 53%-89%) and 60% specificity (CI 31%-83%). In general, SAA results showed numerically lower sensitivity in β-amyloid (Aβ)-positive patients with DLB (70%) compared with Aβ-negative patients with DLB (87.5%) (nonstatistically significant). A fair agreement of SAA results was obtained across the 4 laboratories (average κ = 0.246). This study highlights challenges for the reproducibility of α-syn SAA results across different protocols applied by different laboratories. This finding, together with the methodological variability reported across laboratories, may challenge the clinical implementation of the α-syn SAA. This study provides relevant support for initiating harmonization and standardization of SAA protocols to move the field toward the clinical implementation of SAAs for the biomarker-based diagnosis of DLB. This study provides Class III evidence of variations in the accuracy of CSF α-syn SAA across 4 separate laboratories in distinguishing patients with DLB from healthy controls.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Feb-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41604609/",
      "summary_ja": "背景：レビー小体型認知症（DLB）の診断に有望なα-シヌクレイン（α-syn）シード増幅アッセイ（SAA）は、異なる検査プロトコルの存在が臨床応用の障壁となっている。方法：4つのヨーロッパの研究所で異なるプロトコルを用い、ドーパミントランスポーター陽性の軽度から中等度のDLB患者20名と年齢・性別一致の対照10名の脳脊髄液（CSF）サンプルを解析。独立機関が統計解析を担当した。結果：4研究所の平均感度は78.8％、特異度は77.5％、正確度は78.5％であったが、研究所間で感度55～100％、特異度60～100％とばらつきが大きかった。β-アミロイド陽性DLB患者では感度がやや低下（70％）したが有意差はなかった。研究所間の一致度は低く（κ=0.246）、プロトコルの違いが結果の再現性に影響を与えていることが示唆された。結論：α-syn SAAの臨床導入にはプロトコルの標準化・調和が不可欠であり、本研究はその必要性を支持するエビデンスを提供している。",
      "summary_short_ja": "本研究は、レビー小体型認知症（DLB）診断に用いられるα-シヌクレインシード増幅アッセイ（SAA）の4つの欧州ラボ間での性能を比較した。20例のDLB患者と10例の対照を対象に、各ラボで異なるプロトコルを用いて検査を実施。感度は55～100％、特異度は60～100％とばらつきが大きく、ラボ間の再現性に課題が示された。結果はSAAの臨床導入にはプロトコルの標準化が必要であることを示唆する。",
      "disease": "dementia",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41604608",
      "doi": "10.1111/j.1528-1157.1996.tb00602.x",
      "title": "Progressive Changes in Brain Morphology in People With Idiopathic Generalized Epilepsy.",
      "abstract": "Idiopathic generalized epilepsy (IGE) is typically responsive to treatment, yet some people remain poorly controlled despite multiple antiseizure medication trials. Whether this subgroup shows progressive structural brain changes remains uncertain. We aimed to investigate whether people with poorly controlled chronic IGE exhibit progressive morphological brain alterations and how these differ from those in early-stage IGE. This longitudinal case-control neuroimaging study included 2 cohorts: an early-stage IGE group from West China Hospital (Chengdu, China) and a chronic IGE group from the National Hospital for Neurology and Neurosurgery (London, United Kingdom). Participants had a history of generalized seizures and no focal pathology. Matched healthy controls were drawn from 3 public imaging data sets. Participants underwent 2 high-resolution T1-weighted MRI scans at least 12 months apart. Cortical thickness and hippocampal and subcortical volumes were measured on paired scans. Longitudinal changes were assessed using linear mixed-effects models, correcting for age and interscan interval. Structural covariance analysis was conducted to examine inter-regional relationships over time, focusing on thalamo-cortical coupling. Forty-two people with early-stage IGE and 67 with chronic IGE were recruited from 2 separate epilepsy centers, and 109 matched controls were included. The early-stage IGE group showed progressive atrophy limited to the left putamen. Chronic IGE was associated with widespread cortical thinning, primarily in frontal and temporal regions, and thickening in posterior and occipital areas. Subcortical atrophy involves the putamen, thalamus, and pallidum. People with ongoing generalized tonic-clonic seizures showed thickening in the precentral gyrus and additional thinning in the frontal cortex and precuneus. Photosensitive IGE was associated with thickening in the lingual gyrus and occipital cortex. Valproate use was associated with attenuated structural changes in motor, visual, and subcortical regions. Increased structural covariance was observed between the left thalamus and left lingual gyrus in chronic IGE. Chronic IGE, particularly with persistent generalized tonic-clonic seizures or photosensitivity, is associated with more extensive progressive brain changes compared with matched controls. Valproate may have a protective association with these structural changes, although further validation is needed. Longitudinal MRI may help monitor disease progression and treatment effects in poorly controlled IGE.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Feb-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41604608/",
      "summary_ja": "背景：特発性全般性てんかん（IGE）は通常治療に反応するが、一部の患者は複数の抗てんかん薬を試しても発作が制御困難であり、この群で進行性の脳構造変化が起こるかは不明であった。  \n方法：中国と英国の2施設から早期IGE群（42名）と慢性IGE群（67名）を対象に、健康対照群（109名）と比較した縦断的MRI研究を実施。高解像度T1強調画像を12か月以上の間隔で2回取得し、皮質厚や海馬・皮質下体積を計測。線形混合効果モデルで年齢や検査間隔を補正し、構造的共分散解析で視床皮質結合も評価した。  \n結果：早期IGEでは左被殻の萎縮が限定的に進行。慢性IGEでは前頭葉・側頭葉の皮質薄化と後頭部の肥厚、被殻・視床・淡蒼球の萎縮が広範に認められた。持続性全般性強直間代発作例は前中心回の肥厚と前頭葉・後帯状皮質のさらなる薄化を示し、光過敏IGEは舌状回・後頭皮質の肥厚を伴った。バルプロ酸使用は運動・視覚・皮質下領域の構造変化を抑制する傾向があった。慢性IGEでは左視床と左舌状回間の構造的共分散が増加した。  \n結論：慢性IGE、特に持続性発作や光過敏例は対照群より広範な進行性脳変化を示し、バルプロ酸がこれらの変化を抑制する可能性がある。縦断的MRIは制御困難なIGEの病態進行や治療効果の評価に有用と考えられる。",
      "summary_short_ja": "特発性全般てんかん（IGE）において、治療抵抗性の慢性患者は初期患者に比べて前頭葉や側頭葉を中心に広範な皮質萎縮と一部領域の肥厚を示し、被殻や視床などの皮質下構造も萎縮することが明らかとなった。持続的な全般性強直間代発作や光過敏性を伴う患者では特異的な脳形態変化が認められ、バルプロ酸はこれらの構造変化を抑制する可能性が示唆された。長期的MRI観察は病態進行や治療効果の評価に有用である。",
      "disease": "epilepsy",
      "section": "imaging"
    },
    {
      "source": "pubmed",
      "pmid": "41604607",
      "doi": "10.1212/WNL.0000000000214659",
      "title": "Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.",
      "abstract": "The aim of this study was to describe the long-term effectiveness and treatment persistence of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) in migraine and to identify baseline factors associated with 2-year treatment continuation. A prospective observational multicenter registry-based study of anti-CGRP MAbs was conducted. We analyzed changes in monthly headache days (MHDs) at 24 months (M24) compared with baseline in those who reached M24 (ON-group). We analyzed patterns of response at 4 time points (6, 12, 18, and 24 months). We defined sustained response (SR) as a ≥50% reduction in MHDs at ≥3 of 4 time points. We compared baseline characteristics of the ON-group with those of the discontinuation group because of lack of effectiveness (OFF-group). A total of 1,340 individuals reached M24 (ON-group: median age 48.0 [41.0-55.0] years; 81.7% female). The median MHD at baseline was 20.0 (13.0-28.0) days. At M24, 60.4% of patients demonstrated ≥50% reduction in MHDs (809/1,340). The proportion of participants achieving SR at M24 was 53.8% (142/264). When compared with the ON-group (n = 1,340), the OFF-group (n = 1,057) showed statistically significant higher baseline MHDs (ON: 20.0 [13.0-28.0] vs OFF: 25.0 [16.0-28.0]) and a greater proportion of patients with aura (ON: 16.2% vs OFF: 22.9%), depression (ON: 22.8% vs OFF: 37.9%), and obesity (ON: 7.2% vs OFF: 19.1%) ( Sustained reductions in MHDs to anti-CGRP treatment at 2 years was observed. Delayed treatment onset, migraine with aura, depression, and obesity may negatively affect treatment persistence. This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Feb-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41604607/",
      "summary_ja": "【背景】片頭痛治療における抗CGRPモノクローナル抗体（MAbs）の長期効果と治療継続要因の解明が求められている。  \n【方法】多施設の前向き観察研究で、抗CGRP MAbs治療患者1,340名の24か月後の月間頭痛日数（MHDs）変化を解析。6、12、18、24か月の4時点での反応パターンを評価し、50%以上のMHDs減少が3回以上持続した場合を持続反応（SR）と定義。治療継続群（ON群）と効果不十分で中止した群（OFF群）のベースライン特性を比較。  \n【結果】ON群の中央値MHDは20日から24か月後に60.4%が50%以上減少。SR達成率は53.8%。OFF群はON群に比べ、ベースラインでMHDが多く、片頭痛の前兆、うつ病、肥満の割合が有意に高かった。  \n【結論】抗CGRP MAbsは2年間にわたりMHDを持続的に減少させる効果があり、治療開始の遅れや片頭痛の前兆、うつ病、肥満は治療継続に悪影響を及ぼす可能性が示された。",
      "summary_short_ja": "本研究は、抗CGRPモノクローナル抗体の片頭痛に対する2年間の長期効果と治療継続要因を検討した。1340例で月間頭痛日数が中央値20日から60.4%が50%以上減少し、53.8%が持続的な改善を示した。一方、治療中断群は頭痛日数が多く、オーラ、うつ病、肥満の割合が高かった。これらの因子が治療継続に負の影響を与える可能性が示された。抗CGRP抗体は24か月間にわたり頭痛軽減効果を持続することが示された。",
      "disease": "migraine",
      "section": "treatment"
    },
    {
      "source": "pubmed",
      "pmid": "41592266",
      "doi": "10.1371/journal.pone.0161092",
      "title": "Patterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia.",
      "abstract": "Behavioral and neuropsychiatric symptoms are common in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). However, little is known about their patterns, time course, and association with brain atrophy. We, therefore, aimed to describe behavioral and neuropsychiatric phenotypes in patients with FTD and PPA, leveraging a hypothesis-free/data-driven approach. We included participants diagnosed with behavioral variant FTD (bvFTD) or PPA according to Rascovsky and Gorno-Tempini criteria from the German Center for Neurodegenerative Diseases Clinical Registry Study of Neurodegenerative Diseases-FTD prospective multicenter observational cohort study. Symptoms were assessed using the Neuropsychiatric Inventory-Questionnaire. Principal component analysis (PCA) was used to delineate symptom groups. Subsequently, frequency and severity across diagnostic groups were examined. We applied linear mixed-effects models to describe the longitudinal evolution of symptoms. Associations with MRI-assessed atrophy were investigated using linear regression models. A total of 314 patients (42.4% female, mean age 65.52 [SD 9.0] years) with bvFTD or PPA were included. MRI was available for 134 of 314 individuals. PCA revealed 4 natural symptom groups, labeled active behavioral, passive behavioral, affective, and psychotic phenotypes. Symptom groups were observed at comparable frequencies across diagnostic groups. Time from symptom onset (0.130 [0.044-0.217],  Our findings demonstrate that behavioral and neuropsychiatric symptoms are prevalent in both bvFTD and PPA. Their severity depends on the disease duration, phenotypic group, and sex. This detailed understanding of symptomatology is crucial for optimizing patient care, diagnostic evaluations, and the design of clinical trials. Limitations comprise the lack of neuropathologic validation and the limited availability of MRI data.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Feb-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41592266/",
      "summary_ja": "背景：前頭側頭型認知症（FTD）および一次進行性失語症（PPA）では行動・神経精神症状が多く見られるが、その症状パターンや経過、脳萎縮との関連は十分に解明されていない。  \n方法：ドイツ神経変性疾患センターの多施設前向きコホート研究から、RascovskyおよびGorno-Tempini基準に基づきbvFTDまたはPPAと診断された314名（平均年齢65.5歳）を対象に、神経精神症状をNeuropsychiatric Inventory-Questionnaireで評価。主成分分析（PCA）で症状群を抽出し、線形混合効果モデルで症状の経時変化を解析。MRIデータ（134名分）を用いて萎縮との関連も検討した。  \n結果：PCAにより「能動的行動」「受動的行動」「感情症状」「精神病症状」の4つの症状群が同定され、診断群間で頻度は類似。症状の重症度は発症からの経過時間、症状群、性別に依存し、時間経過とともに変動した。MRI萎縮との関連も示唆された。  \n結論：bvFTDおよびPPAにおける行動・神経精神症状は多様かつ共通しており、症状の理解は診療・診断・臨床試験設計に重要である。神経病理学的検証やMRIデータの限定性が課題である。",
      "summary_short_ja": "前頭側頭型認知症（FTD）および一次進行性失語症（PPA）患者314名を対象に、行動・神経精神症状のパターンと経過をデータ駆動型で解析した。主成分分析により、活動的行動型、受動的行動型、情動型、精神病型の4つの症状群を特定。症状の頻度は診断群間で類似し、重症度は病期や性別に依存した。MRIによる萎縮との関連も検討し、症状理解の深化が診療や臨床試験設計に重要と示唆された。",
      "disease": "dementia",
      "section": "prognosis"
    },
    {
      "source": "pubmed",
      "pmid": "41592265",
      "doi": "10.1212/WNL.0000000000214613",
      "title": "Timing for Starting Antiseizure Medication Withdrawal After Epilepsy Surgery in Adults.",
      "abstract": "More than half of people undergoing epilepsy surgery become seizure-free and may consider withdrawing antiseizure medications (ASMs). Withdrawal practices vary, and the optimal timing remains unclear. We aim to compare seizure relapse risk among individuals initiating ASM withdrawal at different time points after epilepsy surgery. We conducted a multicenter observational cohort study of adults who underwent resective epilepsy surgery between 1990 and 2016 at 12 tertiary centers. Participants were seizure-free before medication withdrawal and had at least 1 year of follow-up. Seizure relapse risk was compared among those initiating withdrawal 1, 2, 3, 4, or 5 years postoperatively vs later. We used propensity score matching for each comparison to adjust for treatment selection bias. Of the 964 people included (51% female; median age at surgery 34 years [interquartile range 26-44]), 446 (46%) began ASM withdrawal in the first year after surgery, 255 (26%) in the second, 110 (11%) in the third, 58 (6%) in the fourth, 29 (3%) in the fifth, and 66 (7%) after the fifth year. After matching, those starting withdrawal in the first (hazard ratio [HR] 1.4;  Initiating ASM withdrawal within the first 2 postoperative years was linked to a higher initial risk of seizure relapse compared with later withdrawal, although long-term outcomes were similar regardless of withdrawal timing. Waiting more than 2 years did not confer additional benefit in reducing seizure risk. Deciding whether and when to withdraw ASMs is a shared process involving individuals, caregivers, and clinicians, balancing preferences, risk of injury, social factors (e.g., driving, work, and supervision), and clinical judgment. Transparent information on risks and benefits is essential. Our findings offer real-world evidence that may inform future evidence-based withdrawal protocols and follow-up strategies.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Feb-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41592265/",
      "summary_ja": "背景：てんかん手術後に発作が消失した成人患者の多くは抗てんかん薬（ASM）を中止することを検討するが、中止開始の最適な時期は不明である。  \n方法：1990～2016年に12の三次医療機関で切除術を受け、術後発作がなく1年以上追跡された964名を対象に、多施設観察コホート研究を実施。術後1～5年目以降でASM中止開始時期別に発作再発リスクを比較し、傾向スコアマッチングで治療選択バイアスを調整した。  \n結果：術後1年以内に中止開始した群は発作再発リスクが高く（HR 1.4）、2年以内の中止も初期リスク増加と関連したが、長期的な発作再発率は中止時期にかかわらず類似。2年以上待つことによる追加のリスク低減効果は認められなかった。  \n結論：ASM中止の開始時期は患者・介護者・医療者がリスクや社会的要因を考慮し共有決定すべきであり、本研究は実臨床に即した中止時期の判断やフォローアップ方針の策定に資するエビデンスを提供する。",
      "summary_short_ja": "てんかん手術後に抗てんかん薬（ASM）をいつ中止するかは最適な時期が不明である。本研究は12施設で1990～2016年に手術を受けた成人964名を対象に、術後1～5年およびそれ以降のASM中止開始時期と発作再発リスクを比較した。術後2年以内の中止は初期の再発リスクが高いが、長期的な発作抑制効果に差はなく、2年以上待つことによる追加の利益は認められなかった。中止時期の決定は患者・家族・医師の協議が重要である。",
      "disease": "epilepsy",
      "section": "treatment"
    },
    {
      "source": "pubmed",
      "pmid": "41576313",
      "doi": "10.1161/STROKEAHA.114.006819",
      "title": "Stroke Technology Diffusion in Rural Settings: Differential Exposure to Certification Levels by Community Income Levels.",
      "abstract": "Although stroke technology and care infrastructure have advanced significantly, it remains unclear whether recent expansions of certified stroke centers have benefited rural patients equitably across income levels. This study assessed whether rural communities of varying income experienced similar gains in access to certified stroke centers and whether such expansions were associated with improvements in acute stroke treatment and outcomes. We conducted a retrospective cohort study using 100% Medicare Provider and Analysis Review data from January 1, 2009, to December 31, 2019. This study included all Medicare fee-for-service beneficiaries diagnosed with acute ischemic stroke who resided in rural US communities. Communities were classified as exposed if a newly certified stroke center-acute stroke ready hospital (ASRH), primary stroke center, thrombectomy-capable stroke center (TSC), or comprehensive stroke center (CSC)-opened within a 30-minute drive. A community fixed-effects linear probability model was used to evaluate changes in outcomes after stroke center certification. Primary outcomes included the following: (1) admission to a stroke-certified hospital, (2) receipt of thrombolytic therapy, (3) receipt of thrombectomy, and (4) one-year mortality. Among 590,191 rural stroke patients, 4% of low-income and 22% of high-income patients had access to a nearby certified stroke center in 2009. By 2019, 30% of low-income and 50% of high-income communities had gained access to at least 1 newly certified stroke center; high-income communities were 3 times more likely than low-income communities to be exposed to a newly certified TSC or CSC (5.4% vs 1.8%). Exposure to ASRHs increased the probability of thrombolysis by 0.63 percentage points (95% 0.05-1.22), whereas exposure to TSC/CSCs increased the probability by 1.39 points (95% CI 0.28-2.49) and thrombectomy by 1.12 points (95% CI 0.41-1.83). No differences in 1-year mortality were observed. During the study period, high-income rural communities experienced more frequent and higher tier stroke center expansion than low-income rural communities. These access disparities were associated with differential gains in advanced stroke treatments, suggesting that expansions may have inadvertently widened income-based disparities in rural stroke care. These findings underscore the need for equity-focused implementation strategies, ensuring that infrastructure improvements translate into equitable clinical benefits.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Feb-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41576313/",
      "summary_ja": "本研究は、脳卒中治療技術の進展が農村部の所得層ごとに平等に恩恵をもたらしているかを検証した。2009年から2019年の米国農村部の急性虚血性脳卒中患者約59万人を対象に、認定脳卒中センターの開設が治療アクセスや臨床結果に与える影響を後ろ向きコホート研究で評価した。コミュニティは、30分圏内に新規認定センター（ASRH、PSC、TSC、CSC）が開設されたかで分類し、入院先、血栓溶解療法、血栓回収術、1年死亡率を主要アウトカムとした。結果、2009年時点で低所得地域の4％、高所得地域の22％が認定センターにアクセス可能であったが、2019年にはそれぞれ30％と50％に増加。特に高所得地域は高度センター（TSC/CSC）へのアクセスが低所得地域の3倍多かった。ASRHへのアクセスは血栓溶解療法の確率を0.63ポイント、TSC/CSCは血栓溶解と血栓回収術の確率をそれぞれ1.39ポイント、1.12ポイント増加させたが、1年死亡率の差はなかった。結論として、高所得農村地域での認定センター拡大がより進み、先進治療の利用格差を拡大させており、所得に基づく不平等を是正するための公平性重視の施策が必要である。",
      "summary_short_ja": "本研究は、2009～2019年の米国農村部における脳卒中認定施設の拡大が所得層によって異なる影響を及ぼしたかを検証した。高所得地域は低所得地域よりも高度な認定施設の増加率が高く、血栓溶解療法や血栓回収術の利用率向上に結びついたが、1年死亡率に差はなかった。結果は、農村部の脳卒中ケアにおける所得格差が拡大している可能性を示し、公平な医療アクセス確保の重要性を示唆している。",
      "disease": "stroke",
      "section": "epidemiology"
    }
  ]
}